The Chain: Protein Engineering Podcast
by Cambridge Healthtech Institute
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 22 chart positions in 22 markets.
By chart position
- 🇬🇧GB · Life Sciences#1115K to 30K
- 🇨🇦CA · Life Sciences#1615K to 30K
- 🇺🇸US · Life Sciences#1815K to 30K
- 🇩🇪DE · Life Sciences#1875K to 30K
- 🇳🇱NL · Life Sciences#3430K to 100K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
77K to 283K🎙 ~2x weekly·87 episodes·Last published 3w ago - Monthly Reach
Unique listeners across all episodes (30 days)
154K to 566K🇳🇱18%🇫🇮18%🇬🇧5%+19 more - Active Followers
Loyal subscribers who consistently listen
46K to 170K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Recent guests
Recent episodes
Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics
Aug 11, 2026
39m 03s
Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care
Jul 14, 2026
45m 08s
Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D
Jun 9, 2026
53m 59s
Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
May 12, 2026
47m 23s
Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design
Apr 15, 2026
38m 49s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/11/26 |  Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics | How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they... | 39m 03s | ||||||
| 7/14/26 | ADCcancer care+4 | Jack Elands | Adcytherix | — | ADCcancer care+5 | — | 45m 08s | ||
| 6/9/26 | AI in biotherapeuticsmachine learning+3 | Andrew Buchanan, Ph.D.Norbert Furtmann, Ph.D. | University of MichiganSanofi | — | AImachine learning+5 | — | 53m 59s | ||
| 5/12/26 | drug discoveryprotein engineering+4 | Daniel Chen | Synthetic Design Lab | — | drug discoveryprotein engineering+4 | — | 47m 23s | ||
| 4/15/26 | protein designautomated pipeline+3 | Martin Pacesa | BindCraftUniversity of Zurich | — | BindCraftprotein binder design+3 | — | 38m 49s | ||
| 3/17/26 | T cell engagementimmune cell engagement+3 | Patrick BaeuerleJeffrey Miller | Cullinan TherapeuticsMasonic Cancer Center | — | T cellimmune cell+6 | — | 58m 44s | ||
| 2/10/26 | biologic therapeuticsmonoclonal antibodies+3 | Paul CarterG. Jonah Rainey+1 | GenentechEli Lilly and Company+1 | — | biologicstherapeutics+5 | — | 49m 08s | ||
| 1/13/26 | cancer immunotherapyresearch evolution+4 | Laszlo Radvanyi | University of TorontoMD Anderson | — | immunotherapycancer+5 | — | 44m 15s | ||
| 12/9/25 | immunogenicitybiologic molecules+4 | Vibha Jawa | EpiVax | — | immunogenicitybiologic molecules+5 | — | 26m 58s | ||
| 11/11/25 | T-cell engagersdrug discovery+3 | Bahija Jallal | Immunocore | — | T-cell engagersdrug development+3 | — | 42m 46s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 10/14/25 | antibody biophysicsdrug development+3 | Shamit Shrivastava | Apoha | — | antibodybiophysics+4 | — | 33m 31s | ||
| 9/16/25 | AI in drug discoverybiotech ecosystem+3 | Derek Lowe | NovartisAI Proteins | — | AIdrug discovery+5 | — | 42m 25s | ||
| 8/12/25 | protein engineeringentrepreneurship+3 | Alexey Lugovskoy | Diagonal Therapeutics | Soviet Union | protein engineeringDiagonal Therapeutics+3 | — | 47m 23s | ||
| 7/29/25 |  Episode: 75 - Are Licensing Fees Required or Gatekeeping? | July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small compa... | 32m 30s | ||||||
| 6/11/25 |  Episode: 74 - Keith Flaherty, President-Elect of AACR, on Public and Private Collabs, AI Optimism, and More | June 10, 2025 | In this bonus episode of The Chain, Daniel Chen, MD, PhD, founder and CEO of Synthetic Design Lab, returns for the Science Commune segment and speaks with Keith Flaherty, MD, FAACR, professor of Medicine of Harvard Medical School and president-elect of AACR. They discuss Flaherty’s prolific career; how his background led him to pursue a career in medicine; how public and private sectors are coming together in oncology around collaborations; reflections on targeted therapies an... | 47m 23s | ||||||
| 6/10/25 |  Episode: 73 - PANEL DISCUSSION: Near-Term Challenges for AI/ML in Biotherapeutic R&D | June 10, 2025 | This episode of The Chain features a panel discussion from May’s PEGS Boston. Moderated by Peter Tessier, Albert M. Mattocks professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, the panelists include Sarel Fleishman, professor of Biomolecular Sciences at the Weizmann Institute of Science; Kadina Johnston, senior specialist of Discovery Biologics at Merck & Co.; Vincent Ling, chief business officer of Morphocell Technologies; Arvind R... | 1h 01m 21s | ||||||
| 5/13/25 |  Episode: 72 - Pamela Barney on HR Lessons to Meet the Needs of Biotech | In this episode of The Chain, host Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC, talks with Pamela Barney, former associate director of HR, AbbVie, about her career within biotech/pharma organizations and some key lessons learned, such as taking advantage of your contacts and network, managing diverse workforces, and HR’s role in creating an engaged team. Barney also discusses why she entered the HR field and the challenges of culture changes when transitioning from a small organization to... | 35m 23s | ||||||
| 4/15/25 |  PEGS Young Scientist Keynote Jessica Stark on the Role of Glycans in Cancer Research | In this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about glycans and why they are important in cancer research. Stark discusses how she became interested in immunology, what her PhD and post-doctoral training was like, her thoughts on singlets operating as part of a network of checkpoint molecules, and what’s currently going on in glycobiology. She also talks about her keynote prese... | 28m 38s | ||||||
| 3/12/25 |  Episode: 70 - Views on Machine Learning and AI in the Antibody and Protein Engineering Space | March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the University of Zurich, discuss AI/ML technologies in the antibody and protein engineering space. Plückthun shares his perspectives on what technologies show promise and success, why the definition of epitope is important when developing a drug, and what aspects he expects to improve in the ML field in the future. | 49m 36s | ||||||
| 2/21/25 |  Episode: 69 - Conversation with Sir Greg Winter on the 50th Anniversary of the Milstein and Köhler Paper | February 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma technology, which paved the way for monoclonal antibodies. Ralph Minter, Biotech CSO/CTO, discusses this important milestone with a true pioneer in the field, Sir Greg Winter, Nobel Laureate and one of the key figures in the development of therapeutic antibodies. | 50m 36s | ||||||
| 12/10/24 |  Episode: 68 - Changing the Game of Protein-Protein Interactions With Randolph Lopez | In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez a... | 46m 00s | ||||||
| 11/12/24 |  Episode: 67 - Anthony Tolcher Discusses Oncology, Dual-Payload Technology, and the ADC Field | November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs,... | 42m 34s | ||||||
| 10/16/24 |  Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond | October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the ... | 39m 43s | ||||||
| 9/10/24 |  Episode 65- Tariq Ghayur on the Renaissance of Bispecifics and ADCs, AI, and More | September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, of Tariq Ghayur Consulting, LLC and Entrepreneur in Residence, FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his journey from BASF Pharma to AbbVie, what it was like when the industry shifted its focus from s... | 31m 55s | ||||||
| 8/13/24 |  Episode: 64 - Peyton Greenside on AI’s Role in Antibody Engineering, Optimization, and More | In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her organization does, what BigHat is doing to ensure the quality of data to train their AI models with, the methods of approaching harder targets such ... | 32m 31s | ||||||
Showing 25 of 91
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for The Chain: Protein Engineering Podcast
Peaked at #11 in Finland, currently #11 in Finland.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Finland | — | #11 | #11 | — |
| Netherlands | — | #34 | #34 | — |
| IS | — | #34 | #34 | — |
| Ireland | — | #46 | #46 | — |
| South Korea | — | #52 | #52 | — |
| CZ | — | #59 | #59 | — |
| IL | — | #60 | #60 | — |
| TR | — | #70 | #70 | — |
| PL | — | #73 | #73 | — |
| SG | — | #73 | #73 | — |
| Finland | — | #78 | #78 | — |
| Japan | — | #79 | #79 | — |
| Italy | — | #82 | #82 | — |
| Denmark | — | #85 | #85 | — |
| TW | — | #87 | #87 | — |
| Spain | — | #109 | #109 | — |
| United Kingdom | — | #111 | #111 | — |
| CH | — | #116 | #116 | — |
| Canada | — | #161 | #161 | — |
| United States | — | #181 | #181 | — |
Chart Positions
23 placements across 22 markets.
Chart Positions
23 placements across 22 markets.